As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloi... ( NEW YORK April 2 2008 -- Pharmac...)

HOME >> BIOLOGY >> TECHNOLOGY

As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report

Date:4/2/2008

NEW YORK, April 2, 2008 /PRNewswire-USNewswire/ -- Pharmaceutical companies currently challenged with replacing the $65 billion worth of product expected to go off patent in the next four years must dramatically rethink their R&D models for future success, according to a new report released by Deloitte today.

According to the report titled The Changing Face of R&D in the Future Pharmaceutical Landscape (http://www.deloitte.com/us/FuturePharma), current R&D programs focused on developing a small portfolio of high revenue blockbusters will evolve to R&D programs focused on high efficacy treatments developed for smaller patient populations based on specific genotypes. Such treatments, and their higher demonstrated efficacy, may ultimately have the potential for higher per treatment revenues.

This fundamental disruption of today's pharmaceutical industry will create both opportunities and threats for current industry players, and will stimulate the emergence of new industry entrants configured specifically to succeed in the changed pharmaceutical landscape.

"Continuing yesterday's R&D focus on developing blockbusters will not secure success in the future," according to Terri Cooper, Ph.D., a principal in the Life Sciences practice of Deloitte Consulting LLP. "Pharmaceutical companies cannot rest on their laurels. They need to be looking outside of their four walls to develop partnerships and collaborations with a network of companies, scientists and organizations to fuel R&D developments and reduce time to bring new drugs to market."

The R&D model of the future will incorporate:

-- R&D strategies which support the assembly of treatment portfolios for the entire disease life cycle and the various genotype specific patient segments in the life cycle, rather than the traditional one-off "blockbuster"

-- Focused R&D programs based on genotyped patie
'/>"/>

SOURCE Deloitte
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
6. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
7. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
8. Profarmas Gross Revenue Reached R$ 740,4 Million in the 4th Quarter of 2007, a 40,1% Growth Over the Same Period in the Last Year
9. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
10. Phlo Reports Sharp Revenue Increase
11. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007

Post Your Comments:

(Date:12/1/2009)...A, Dec. 1 GeoVax Labs, ...an Atlanta-based, biopharmaceutical company develo...Human Immunodeficiency Virus) and other infectious...S Day. ,, "Today is the 21st World AIDS Day and...fight with the HIV/AIDS pandemic, we remain focuse...

(Date:12/1/2009)... A new clinical study presented to the Americ...ree-dimensional (3-D) automated ultrasound follicl...n in vitro fertilization (IVF) cycle is effective ...ment of the follicles. , ...d Fertility Center of Chicago has just completed r...

(Date:12/1/2009)... iCardiac now provides services to three out ... Rochester, NY (PRWEB) Decem...al leader in advanced cardiac core lab services an...rmaceutical company has selected iCardiac as a pre...will provide Highly Automated QT(sm) and Dynamic Q...

(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of the h...; Technologies, a business development and intelle...merging nanotechnology space. The company also pl... a nanotechnology incubator. , ...chael R. Drapp , a 34-year veteran of the high-tec...

Breaking Biology Technology:GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6 Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2 Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3 Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2 Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2 Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3 Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4

[0] GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress [0] Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch [0] Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services [0] Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution

...T. CHARLES, Mo., Oct. 2 Ameristar Casinos,Inc. (N...nual Ameristar,National Charity Golf Classic, host... philanthropic arm, has raised more than $1.1 mill...re Paralysis and The Christopher &,Dana Reeve Foun... Ameristar Casino Resort Spa,and the Whitmoor Coun...

...DIDATE ARIKACE(TM) DRIVES,CONTINUED CLINICAL EXPAN...Inc., a,biopharmaceutical company focused on devel...ite-specific treatment of serious lung diseases,to...venture loan from CIT,Healthcare and Compass Horiz...chnology Finance Management LLC., In June, Transa...

...Corp. (NYSE: CMN ) will hold a conference call to...ter and fiscal year ended July 31, 2008 on,October...l will be Charles,M. Diker, Chairman; Andrew A. Kr...ident-Corporate Development and Strategy; Craig A..... Malkin, President of Minntech,Corporation. Minnt...

Other Biology Technology:Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation 2 Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation 3 Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation 4 Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation 5 Transave, Inc. Secures $12.5 Million in New Financing 2 Transave, Inc. Secures $12.5 Million in New Financing 3 Transave, Inc. Secures $12.5 Million in New Financing 4 Transave, Inc. Secures $12.5 Million in New Financing 5 Cantel Medical Corp. To Hold Conference call to Discuss Fourth Quarter and Fiscal 2008 Results 2

Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation Transave, Inc. Secures $12.5 Million in New Financing Cantel Medical Corp. To Hold Conference call to Discuss Fourth Quarter and Fiscal 2008 Results

(Date:12/1/2009)..., Antennas aren,t just for listening to the radio ...es to GPS devices. Research from North Carolina St...enna design creating shape-shifting antennas that...ging from public safety to military deployment. ,...tals, but there are limitations to how far they ca...

(Date:11/30/2009)...Those extra helpings of gravy and dessert at the h...line than previously thought. According to a new r...ASEB Journal ( http://www.fasebj.org ), a diet th...n genes that ultimately cause our bodies to store ...a double-whammy as the already difficult task of c...

(Date:11/30/2009)... This release is available in German . , Th...laborative Research Centres as of 1 January 2010. ...ants Committee in Bonn. The new centres will initi...million. In addition, 20 percent overhead funding ...project. The centres, research topics range from m...

[0] Shape shifters: Researchers create new breed of antennas [0] Happy holidays from the groaning board; Western diets turn on fat genes [0] DFG approves funding for 17 new collaborative research centers

... systematic review highlights strong results from ...or worldwide use of the low-cost drug Bactrim to h... reviewers surveyed medical literature on the prev...s for the generic medicine cotrimoxazole -- for ch...eadly to a person whose immune system is weakened ...

...rvation scientists generally agree that many types...ical forests. However, little is known about the c...d reserves in slowing the most extreme form of for...a paper recently published in Conservation Biology...m of scientists, led by Daniel Nepstad of the Wood...

...rchers at Yale School of Medicine have found evide...y stimulates the higher brain functions of spatial...ests that we may learn best on an empty stomach. ,...re Neuroscience by investigators at Yale and other...elin, produced in the stomach and previously assoc...

Other Biology News:Low-cost drug gaining favor for use in HIV-infected children in poor countries 2 Satellites show Amazon parks, indigenous reserves stop forest clearing 2 Satellites show Amazon parks, indigenous reserves stop forest clearing 3 Learning and memory stimulated by gut hormone 2

Low-cost drug gaining favor for use in HIV-infected children in poor countries Satellites show Amazon parks, indigenous reserves stop forest clearing Learning and memory stimulated by gut hormone

G(5)ppp(5)G from Ambion

High-Binding EIA 96 Well Plates from Cayman Chemical

Human Atherosclerosis Antibody Array I Kit, ChemiArray, 20 cytokines per membrane from CHEMICON

Rabbit Complement from Equitech-Bio

Biology Products:

G(5)ppp(5)G from Ambion High-Binding EIA 96 Well Plates from Cayman Chemical Human Atherosclerosis Antibody Array I Kit, ChemiArray, 20 cytokines per membrane from CHEMICON Rabbit Complement from Equitech-Bio

As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloi...( NEW YORK April 2 2008 -- Pharmac...)